-
Veliparib in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Not Recruiting
More
This phase II trial studies how well veliparib works in treating patients with epithelial
ovarian, fallopian tube, or primary peritoneal cancer that has come back or does not respond
to treatment. Veliparib may stop the growth of tumor cells by blocking some of the enzymes
needed for cell growth.
Stanford is currently not accepting patients for this trial.
For more information, please contact Maureen Sutton, 6507259167.
Stanford Investigators
View full details
-
Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer
Not Recruiting
More
This randomized phase II/III trial studies how well paclitaxel, carboplatin, and metformin
hydrochloride works and compares it to paclitaxel, carboplatin, and placebo in treating
patients with endometrial cancer that is stage III, IV, or has come back. Drugs used in
chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth
of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping
them from spreading. Metformin hydrochloride may help paclitaxel and carboplatin work better
by making cancer cells more sensitive to the drugs. It is not yet known whether paclitaxel
and carboplatin is more effective with or without metformin hydrochloride in treating
endometrial cancer.
Stanford is currently not accepting patients for this trial.
For more information, please contact Suzanne Friedrich, 650-725-0436.
Stanford Investigators
View full details
-
Zoledronate or Observation in Maintaining Bone Mineral Density in Patients Who Are Undergoing Surgery to Remove Both Ovaries
Not Recruiting
More
This randomized phase II trial is studying zoledronate to see how well it works compared to
observation in maintaining bone mineral density in patients who are undergoing surgery to
remove both ovaries. Zoledronate may prevent bone loss in patients who are undergoing surgery
to remove the ovaries.
Stanford is currently not accepting patients for this trial.
For more information, please contact Maureen Sutton, 6507259167.
Stanford Investigators
View full details
-
Health and Recovery Program in Increasing Physical Activity Level in Stage IA-IIIA Endometrial Cancer Survivors
Not Recruiting
More
This randomized phase II trial studies how well a health and recovery program works in
increasing physical activity level in stage IA-IIIA endometrial cancer survivors. Health and
recovery program which includes exercise counseling, Fitbit tracker, and phone or email/text
communication may increase the level of physical activity in endometrial cancer survivors and
promote and maintain behavior change at a lower cost.
Stanford is currently not accepting patients for this trial.
For more information, please contact Melissa Usoz, 650-723-8843.
Lead Sponsor
Stanford Investigators
View full details
-
Selumetinib Sulfate in Treating Woman With Recurrent Low-Grade Ovarian Cancer or Peritoneum Cancer
Not Recruiting
More
This phase II trial studies the side effects and how well selumetinib sulfate works in
treating patients with low-grade ovarian cancer that has come back (recurrent). Selumetinib
sulfate may stop the growth of tumor cells by blocking some of the enzymes needed for cell
growth.
Stanford is currently not accepting patients for this trial.
For more information, please contact Maureen Sutton, 6507259167.
Stanford Investigators
View full details
-
Safety and Efficacy Clinical Study of SNS-595 in Patients With Platinum-Resistant Ovarian Cancer
Not Recruiting
More
The purpose of this study is to evaluate the objective response rate, safety and identify
potential biomarkers in platinum-resistant ovarian cancer patients treated with voreloxin
injection given on a 28-day cycle.
Stanford is currently not accepting patients for this trial.
For more information, please contact Maureen Sutton, 6507259167.
Stanford Investigators
View full details
-
Doxorubicin Hydrochloride, Cisplatin, and Paclitaxel or Carboplatin and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer
Not Recruiting
More
This randomized phase III trial compares how well two different combination chemotherapy
regimens (doxorubicin hydrochloride, cisplatin, and paclitaxel versus carboplatin and
paclitaxel) work in treating patients with endometrial cancer that is stage III-IV or has
come back (recurrent). Drugs used in chemotherapy such as doxorubicin hydrochloride,
cisplatin, paclitaxel, and carboplatin, work in different ways to stop the growth of tumor
cells, either by killing the cells, by stopping them from dividing, or by stopping them from
spreading. It is not yet known which combination chemotherapy regimen is more effective in
treating endometrial cancer.
Stanford is currently not accepting patients for this trial.
For more information, please contact Maureen Sutton, 6507259167.
Stanford Investigators
View full details
-
Safety and Efficacy Study of Catumaxomab to Treat Ovarian Cancer After a Complete Response to Chemotherapy
Not Recruiting
More
The purpose of this study is to determine whether the investigational drug catumaxomab
delivered in the planned treatment schedule is a safe and effective treatment for women with
advanced ovarian cancer who experience a complete response to chemotherapy.
Stanford is currently not accepting patients for this trial.
For more information, please contact Colleen Fitzsimmons, 6507243155.
Stanford Investigators
View full details
-
Efficacy and Safety of Farletuzumab (MORAb-003) in Combination With Carboplatin and Taxane in Participants With Platinum-sensitive Ovarian Cancer in First Relapse
Not Recruiting
More
This research is being done to find out if Carboplatin and Taxane works better alone or when
given with an experimental drug called MORAb-003(farletuzumab) in subjects with first
platinum sensitive relapsed ovarian cancer.
Stanford is currently not accepting patients for this trial.
For more information, please contact Anthea Buchin, 6507243155.
Stanford Investigators
View full details
-
A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2)
Not Recruiting
More
The purpose of this study is to determine which patients with ovarian, fallopian tube, and
primary peritoneal cancer will best respond to treatment with rucaparib.
Stanford is currently not accepting patients for this trial.
For more information, please contact Alma Gonzalez, 650-498-0624.
Stanford Investigators
View full details
-
Pazopanib Plus Lapatinib Compared to Lapatinib Alone and Pazopanib Alone In Subjects With Metastatic Cervical Cancer
Not Recruiting
More
This study is being conducted to compare the efficacy and safety of pazopanib in combination
with lapatinib with that of lapatinib alone or pazopanib alone in subjects with metastatic
cervical cancer
Stanford is currently not accepting patients for this trial.
For more information, please contact Tine Bjornlund, 6507259167.
Stanford Investigators
View full details
-
Clinical Trial for Ovarian Cancer (OvaRex®)
Not Recruiting
More
This study will compare the time to disease relapse between OvaRex® MAb-B43.13-treated
patients and placebo-treated patients. This study will also compare assessments of survival,
quality of life, immune response and safety between active and placebo groups.
Stanford is currently not accepting patients for this trial.
For more information, please contact Jim Batterson, 6507255974.
Stanford Investigators
View full details
-
Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer
Not Recruiting
More
This randomized phase III trial studies paclitaxel and carboplatin see how well they work
compared with paclitaxel and ifosfamide in treating patients with fallopian tube, or
peritoneal cavity cancer that is newly diagnosed, persistent, or has come back (recurrent).
Drugs used in chemotherapy, such as paclitaxel, carboplatin, and ifosfamide, work in
different ways to stop the growth of tumor cells, either by killing the cells, by stopping
them from dividing, or by stopping them from spreading. It is not yet known whether
paclitaxel is more effective when given with carboplatin or ifosfamide in treating patients
with uterine, ovarian, fallopian tube, or peritoneal cavity cancer.
Stanford is currently not accepting patients for this trial.
For more information, please contact Maureen Sutton, 6507259167.
Stanford Investigators
View full details
-
TRINOVA-1: A Study of AMG 386 or Placebo, in Combination With Weekly Paclitaxel Chemotherapy, as Treatment for Ovarian Cancer, Primary Peritoneal Cancer and Fallopian Tube Cancer
Not Recruiting
More
The purpose of this study is to determine if treatment with paclitaxel plus AMG 386 is
superior to paclitaxel plus placebo in women with recurrent partially platinum sensitive or
resistant epithelial ovarian cancer, primary peritoneal cancer or fallopian tube cancer.
AMG 386 is a man-made medication that is designed to stop the development of blood vessels in
cancer tissues. Cancer tissues rely on the development of new blood vessels, a process called
angiogenesis, to obtain a supply of oxygen and nutrients to grow.
Stanford is currently not accepting patients for this trial.
For more information, please contact Maureen Sutton, 6507259167.
Stanford Investigators
View full details
-
Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer
Not Recruiting
More
This randomized phase III trial studies the side effects of paclitaxel when given together
with cisplatin or topotecan with or without bevacizumab and to compare how well they work in
treating patients with stage IVB, cervical cancer that has come back or is persistent. Drugs
used in chemotherapy, such as paclitaxel, cisplatin, and topotecan, work in different ways to
stop the growth of tumor cells, either by killing the cells, by stopping them from dividing,
or by stopping them from spreading. Monoclonal antibodies, such as bevacizumab, may interfere
with the ability of tumor cells to grow and spread. It is not yet known whether paclitaxel is
more effective when given together with cisplatin or topotecan with or without bevacizumab in
treating patients with cervical cancer.
Stanford is currently not accepting patients for this trial.
For more information, please contact Maureen Sutton, 6507259167.
Stanford Investigators
View full details
-
Chemotherapy Toxicity On Quality of Life in Older Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer
Not Recruiting
More
This trial studies the chemotherapy toxicity on quality of life in older patients with stage
I, stage II, stage III, or stage IV ovarian epithelial, primary peritoneal cavity, or
fallopian tube cancer. Learning about the side effects of chemotherapy in older patients may
help doctors plan better ways to treat cancer.
Stanford is currently not accepting patients for this trial.
For more information, please contact Sharanya Ramasubramanian, 650-723-0622.
Stanford Investigators
View full details
-
A Study of GDC-0980 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Not Recruiting
More
This is a multicenter, single-arm, open-label Phase II study to evaluate the activity of
GDC-0980 in patients with recurrent or persistent endometrial cancer. The safety,
tolerability, and pharmacokinetics of GDC-0980 will also be evaluated.
Stanford is currently not accepting patients for this trial.
For more information, please contact Anthea Buchin, 6507243155.
Stanford Investigators
View full details
-
Temsirolimus With or Without Megestrol Acetate and Tamoxifen Citrate in Treating Patients With Advanced, Persistent, or Recurrent Endometrial Cancer
Not Recruiting
More
This randomized phase II trial studies how well temsirolimus with or without megestrol
acetate and tamoxifen citrate works in treating patients with endometrial cancer that has
spread to other places in the body and usually cannot be cured or controlled with treatment,
has returned after a period of improvement, or is persistent. Temsirolimus may stop the
growth of tumor cells by blocking some of the enzymes needed for cell growth. Estrogen can
cause the growth of endometrial cancer cells. Hormone therapy using megestrol acetate and
tamoxifen citrate may fight endometrial cancer by blocking the use of estrogen by the tumor
cells. It is not yet known whether temsirolimus is more effective when given alone or
together with megestrol acetate and tamoxifen citrate in treating endometrial cancer.
Stanford is currently not accepting patients for this trial.
For more information, please contact Maureen Sutton, 6507259167.
Stanford Investigators
View full details
-
Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
Not Recruiting
More
This randomized phase III trial studies bevacizumab and intravenous (given into a vein)
chemotherapy to see how well they work compared with bevacizumab and intraperitoneal (given
into the abdominal cavity) chemotherapy in treating patients with stage II-III ovarian
epithelial cancer, fallopian tube cancer, or primary peritoneal cancer. Monoclonal
antibodies, such as bevacizumab, can block the ability of tumor cells to grow and spread by
blocking the growth of new blood vessels necessary for tumor growth. Drugs used in
chemotherapy, such as paclitaxel, carboplatin, and cisplatin, work in different ways to stop
the growth of tumor cells, either by killing the cells or by stopping them from dividing. It
is not yet known whether giving bevacizumab together with intravenous chemotherapy is more
effective than giving bevacizumab together with intraperitoneal chemotherapy in treating
patients with ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cancer.
Stanford is currently not accepting patients for this trial.
For more information, please contact Maureen Sutton, 6507259167.
Stanford Investigators
View full details
-
Cisplatin and Radiation Therapy With or Without Tirapazamine in Treating Patients With Cervical Cancer
Not Recruiting
More
This randomized phase III trial is studying cisplatin, radiation therapy, and tirapazamine to
see how well they work compared to cisplatin and radiation therapy in treating patients with
cervical cancer. Drugs used in chemotherapy, such as cisplatin and tirapazamine, work in
different ways to stop the growth of tumor cells, either by killing the cells or by stopping
them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Internal
radiation uses radioactive material placed directly into or near a tumor to kill tumor cells.
Cisplatin and tirapazamine may make tumor cells more sensitive to radiation therapy. It is
not yet known whether giving cisplatin together with radiation therapy is more effective with
or without tirapazamine in treating cervical cancer.
Stanford is currently not accepting patients for this trial.
For more information, please contact Maureen Sutton, 6507259167.
Stanford Investigators
View full details
-
Clinical Trial of Lurbinectedin (PM01183) in Platinum Resistant Ovarian Cancer Patients
Not Recruiting
More
Multicenter, open-label, randomized, controlled phase III clinical trial to evaluate the
activity and safety of PM01183 versus PLD or topotecan as control arm in patients with
platinum-resistant ovarian cancer. PM01183 will be explored as single agent in the
experimental arm (Arm A) versus PLD or topotecan in the control arm (Arm B).
Stanford is currently not accepting patients for this trial.
For more information, please contact Aarti Kale, 650-723-0622.
Stanford Investigators
View full details
-
Tissue and Plasma Biomarkers of Lymph Node Involvement in Cervical Cancer
Not Recruiting
More
The purpose of this study is to measure the levels of serum proteins and other biomarkers in
cervical cancer patients. We believe that some of these markers may be useful in selecting
patients for specific types of cancer therapies. These markers may also help to predict
response to therapy, relapse after therapy, and survival after therapy.
Stanford is currently not accepting patients for this trial.
For more information, please contact Dylann Fujimoto, 650-723-8843.
Lead Sponsor
Stanford Investigators
View full details
-
Overcoming Obstacles to Clinical Trials Enrollment Through a Navigator Program
Not Recruiting
More
Pilot study for assessing the effectiveness of a Navigator program to aid in clinical trial
participation amongst the Chinese demographic
Stanford is currently not accepting patients for this trial.
For more information, please contact Mei-Chin Kuo, 6507361977.
Lead Sponsor
Stanford Investigators
View full details
-
Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer
Not Recruiting
More
This randomized phase III trial studies carboplatin and paclitaxel to see how well they work
with or without cisplatin and radiation therapy in treating patients with stage I-IVA
endometrial cancer. Drugs used in chemotherapy, such as carboplatin, paclitaxel, and
cisplatin, work in different ways to stop the growth of tumor cells, either by killing the
cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy
uses high-energy x-rays to kill tumor cells. Giving chemotherapy and radiation therapy after
surgery may kill any tumor cells that remain after surgery. It is not yet known whether
carboplatin and paclitaxel are more effective with or without cisplatin and radiation therapy
in treating patients with endometrial cancer.
Stanford is currently not accepting patients for this trial.
For more information, please contact Maureen Sutton, 6507259167.
Stanford Investigators
View full details
-
Monoclonal Antibody (mAb) 216 With Chemotherapy in Adult Relapsed or Refractory B-Lineage Acute Lymphoblastic Leukemia
Not Recruiting
More
A phase I trial in patients with relapsed or refractory leukemia of a human monoclonal
antibody that kills B cell acute lymphoblastic leukemia. Trial will study safety,
pharmacokinetics, and anti tumor activity of the antibody given as a single agent and with
vincristine.
Stanford is currently not accepting patients for this trial.
For more information, please contact SPECTRUM, .
Stanford Investigators
View full details
-
Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer
Not Recruiting
More
This phase II/III trial studies how well trametinib works and compares it to standard
treatment with either letrozole, tamoxifen, paclitaxel, pegylated liposomal doxorubicin, or
topotecan in treating patients with low-grade ovarian cancer or peritoneal cavity cancer that
has come back (recurrent), become worse (progressive), or spread to other parts of the body.
Trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell
growth. It is not yet known whether trametinib is more effective than standard therapy in
treating patients with ovarian or peritoneal cavity cancer.
Stanford is currently not accepting patients for this trial.
For more information, please contact Madelyn Gutierrez Gomez, 650-723-0298 .
Stanford Investigators
View full details
-
A Study of Carboplatin and Gemcitabine Plus Bevacizumab in Patients With Ovary, Peritoneal, or Fallopian Tube Carcinoma
Not Recruiting
More
This is a placebo-controlled, randomized, multicenter Phase III study that will evaluate the
safety and efficacy of bevacizumab, administered in combination with carboplatin with
gemcitabine, in women with platinum-sensitive recurrent epithelial ovarian, primary
peritoneal, or fallopian tube carcinoma.
Stanford is currently not accepting patients for this trial.
For more information, please contact Sarah Charlesworth, 6507960344.
Stanford Investigators
View full details
-
OPT-821 With or Without Vaccine Therapy in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in Second or Third Complete Remission
Not Recruiting
More
This randomized phase II trial studies OPT-821 and vaccine therapy to see how well they work
compared with OPT-821 alone in treating patients with ovarian epithelial cancer, fallopian
tube cancer, or peritoneal cancer that has decreased or disappeared, but the cancer may still
be in the body. Biological therapies, such as OPT-821, may stimulate the immune system in
different ways and stop tumor cells from growing. Vaccines may help the body build an
effective immune response to kill tumor cells. It is not yet known whether OPT-821 is more
effective with or without vaccine therapy in treating patients with ovarian epithelial
cancer, fallopian tube cancer, or peritoneal cancer.
Stanford is currently not accepting patients for this trial.
For more information, please contact Maureen Sutton, 6507259167.
Stanford Investigators
View full details
-
Second-Line Therapy Study For Potentially Platinum-Sensitive Relapsed Ovarian Cancer
Not Recruiting
More
This study was designed to find the most effective and safest doses of both HYCAMTIN and
CARBOPLATIN that can be given for the treatment of ovarian cancer. This study may allow
researchers to determine the effectiveness of combining HYCAMTIN and CARBOPLATIN.
Stanford is currently not accepting patients for this trial.
For more information, please contact Tine Bjornlund, 6507259167.
Stanford Investigators
View full details
-
Ovarian Cancer Vaccine for Patients in Remission
Not Recruiting
More
The purpose of this study is to determine the safety and efficacy of an investigational
therapeutic agent (Cvac) in ovarian cancer patients in first or second remission and to
determine its ability to prevent cancer from returning.
Study objectives
Primary objectives:
- To confirm the safety of administering Cvac in this population.
- To determine the effects of Cvac on progression-free survival (PFS).
Secondary objectives:
- To determine overall survival (OS) for ovarian cancer patients who receive Cvac after
achieving remission in the first or second-line setting.
- Evaluation of host immunologic response to Cvac administration.
Stanford is currently not accepting patients for this trial.
For more information, please contact Anthea Buchin, 6507243155.
Stanford Investigators
View full details
-
Study to Compare the Efficacy and Safety of Olaparib When Given in Combination With Carboplatin and Paclitaxel, Compared With Carboplatin and Paclitaxel in Patients With Advanced Ovarian Cancer
Not Recruiting
More
To compare the efficacy of olaparib in combination with paclitaxel and carboplatin (AUC4)
when compared with carboplatin (AUC6) and paclitaxel alone in patients with advanced ovarian
cancer.
Stanford is currently not accepting patients for this trial.
For more information, please contact Colleen Fitzsimmons, 6507243155.
Stanford Investigators
View full details
-
Dose Escalation Study of OMP-54F28 in Combination With Paclitaxel and Carboplatin in Patients With Recurrent Platinum-Sensitive Ovarian Cancer
Not Recruiting
More
This is an open-label Phase 1b dose-escalation study to assess the safety, tolerability, and
PK of OMP-54F28 when combined with paclitaxel and carboplatin. OMP-54F28 will be administered
IV on Days 1 of each 21-day cycle. Paclitaxel (175 mg/m2) and carboplatin (AUC = 5 mg/mL •
min) will be administered IV on Day 1 of each cycle. A total of 6 cycles of paclitaxel and
carboplatin will be given. Additional cycles may be given as per institutional standard of
care after discussion with the Medical Monitor. Treatment with OMP-54F28 will continue after
completion of treatment with paclitaxel and carboplatin. The planned dose levels of OMP-54F28
are 5 and 10 mg/kg.
Stanford is currently not accepting patients for this trial.
For more information, please contact Ashley Powell, 650-724-3308.
Stanford Investigators
View full details
-
Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy.
Not Recruiting
More
Olaparib Monotherapy in Patients with BRCA Mutated Ovarian Cancer following First Line
Platinum Based Chemotherapy.
Stanford is currently not accepting patients for this trial.
For more information, please contact Suzanne Friedrich, 650-725-0426.
Stanford Investigators
View full details
-
Cetuximab in Treating Patients With Persistent or Recurrent Cervical Cancer
Not Recruiting
More
This phase II trial is studying cetuximab to see how well it works in treating patients with
persistent or recurrent cervical cancer. Monoclonal antibodies, such as cetuximab, can block
tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
Others find tumor cells and help kill them or carry tumor-killing substances to them.
Stanford is currently not accepting patients for this trial.
For more information, please contact Maureen Sutton, 6507259167.
Stanford Investigators
View full details
-
Study of FP-1039 in Subjects With Endometrial Cancers
Not Recruiting
More
An open-label, non-randomized, single arm study to assess the safety, tolerability, and
pharmacokinetics of FP-1039 given by weekly intravenous (IV) administrations in advanced
endometrial cancer patients with FGFR2-specific mutations. FP-1039 will be dosed weekly
starting at a dose of up to 16 mg/kg.
Stanford is currently not accepting patients for this trial.
For more information, please contact Dana Supan, 6507361694.
Stanford Investigators
View full details
-
Study of the Trifunctional Antibody Catumaxomab to Treat Recurrent Symptomatic Malignant Ascites
Not Recruiting
More
The purpose of this study is to determine whether the investigational drug catumaxomab is a
safe and effective treatment for recurrent symptomatic malignant ascites.
Stanford is currently not accepting patients for this trial.
For more information, please contact Colleen Fitzsimmons, 6507243155.
Stanford Investigators
View full details
-
A Study of HGS1036 in Combination With Chemotherapy in Subjects With Advanced Solid Malignancies
Not Recruiting
More
The primary purpose of this study is to determine the maximally tolerated dose (MTD) of
HGS1036 when used in combination with the standard chemotherapeutic regimens paclitaxel plus
carboplatin, cisplatin plus etoposide, or docetaxel.
Stanford is currently not accepting patients for this trial.
For more information, please contact Jennifer Vargas, 650-723-0371 .
Stanford Investigators
View full details
-
Cvac as Maintenance Treatment in Patients With Epithelial Ovarian Cancer in Complete Remission Following First-line Chemotherapy or Second-line Treatment
Not Recruiting
More
As < 10% of the necessary patients required by the protocol were recruited and the data were
not intended to support a labeling claim, it was determined that the abbreviated clinical
study report (CSR) was the appropriate reporting format. No efficacy analyses were performed
as the trial was terminated early with incomplete enrollment of < 10%.
The purpose of this study is to determine if an investigational cell therapy called Cvac can
help epithelial ovarian cancer (EOC) from returning when administered to patients who are in
complete remission after surgical removal of their tumor followed by standard first-line
(Part A) or second-line (Part B) chemotherapy. Following remission, patients will undergo
leukapheresis for the manufacture of the study agent. After completion of chemotherapy and
confirmation of remission, patients will enter the treatment phase of the study.
Stanford is currently not accepting patients for this trial.
For more information, please contact Kashif Naseem, 650-724-3155.
Stanford Investigators
View full details
-
A Controlled Study of the Effectiveness of Oregovomab (Antibody) Plus Chemotherapy in Advanced Ovarian Cancer
Not Recruiting
More
This is a Phase 2 randomized study with two treatment arms to compare the effectiveness of
oregovomab (a murine monoclonal antibody directed against cancer antigen 125 (CA125)) when
combined with first-line chemotherapy (carboplatin and paclitaxel) to first-line chemotherapy
(carboplatin and paclitaxel alone) in female patients with advanced ovarian cancer.
Stanford is currently not accepting patients for this trial.
For more information, please contact Ashley Powell, 650-724-3308.
Stanford Investigators
View full details
-
A Study of Adavosertib (MK-1775) in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone for Participants With Platinum-Sensitive Ovarian Tumors With the P53 Gene Mutation (MK-1775-004)
Not Recruiting
More
This is a study of the safety and efficacy of adavosertib in combination with paclitaxel plus
carboplatin in the treatment of ovarian, fallopian tube, and primary peritoneal tumors with
the P53 mutation. In Part 1, a small group of participants will receive adavosertib along
with paclitaxel plus carboplatin to establish the tolerability of adavosertib with this
combination. In Part 2, participants will be randomly assigned to receive either adavosertib
plus paclitaxel and carboplatin OR placebo plus paclitaxel and carboplatin to assess efficacy
of adavosertib compared to placebo. The primary hypothesis of the study (Part 2) is that
administration of adavosertib in combination with paclitaxel plus carboplatin in participants
with platinum sensitive p53 mutant ovarian cancer will result in improvement in progression
free survival (PFS) per enhanced Response Evaluation Criteria In Solid Tumors version 1.1
(enhanced RECIST 1.1) compared to participants treated with paclitaxel plus carboplatin
alone.
Stanford is currently not accepting patients for this trial.
For more information, please contact Kashif Naseem, 650724-3155.
Stanford Investigators
View full details
-
Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
Not Recruiting
More
This randomized phase III trial studies carboplatin, paclitaxel, and bevacizumab to see how
well they work compared to carboplatin, paclitaxel, and placebo in treating patients with
stage III or stage IV ovarian epithelial, primary peritoneal, or fallopian tube cancer. Drugs
used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the
growth of tumor cells, either by killing the cells or by stopping them from dividing.
Monoclonal antibodies, such as bevacizumab, may interfere with the ability of tumor cells to
grow and spread. It is not yet known whether carboplatin, paclitaxel, and bevacizumab are
more effective than carboplatin, paclitaxel, and placebo in treating ovarian epithelial,
primary peritoneal, or fallopian tube cancer.
Stanford is currently not accepting patients for this trial.
For more information, please contact Tine Bjornlund, 6507259167.
Stanford Investigators
View full details
-
Phase I Stereotactic Body Radiation for Metastatic or Recurrent Platinum-Resistant Ovarian Cancer
Not Recruiting
More
This phase I trial studies the side effects and the best dose of stereotactic body radiation
therapy (SBRT) in treating patients with metastatic or recurrent ovarian cancer or primary
peritoneal cancer. SBRT may be able to send x-rays directly to the tumor and cause less
damage to normal tissue.
Stanford is currently not accepting patients for this trial.
For more information, please contact Elizabeth A. Kidd, 650-725-2174.
Lead Sponsor
Stanford Investigators
View full details
-
Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
Not Recruiting
More
This phase III clinical trial studies two different dose schedules of paclitaxel to see how
well they work in combination with carboplatin with or without bevacizumab in treating
patients with stage II, III or IV ovarian epithelial cancer, primary peritoneal cancer, or
fallopian tube cancer. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work
in different ways to stop the growth of tumor cells, either by killing the cells, by stopping
them from dividing, or by stopping them from spreading. Bevacizumab is a type of drug called
a monoclonal antibody and blocks tumor growth by stopping the growth of blood vessels that
tumors need to grow. It is not yet known whether giving paclitaxel with combination
chemotherapy once every three weeks is more effective than giving paclitaxel once a week in
treating patients with ovarian, primary peritoneal, or fallopian tube cancer.
Stanford is currently not accepting patients for this trial.
For more information, please contact Maureen Sutton, 6507259167.
Stanford Investigators
View full details
-
Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
Not Recruiting
More
This randomized phase III trial studies carboplatin, paclitaxel and gemcitabine hydrochloride
when given together with or without bevacizumab after surgery to see how well it works in
treating patients with ovarian, epithelial, primary peritoneal, or fallopian tube cancer that
has come back. Drugs used in chemotherapy, such as carboplatin, paclitaxel and gemcitabine
hydrochloride work in different ways to stop the growth of tumor cells, either by killing the
cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with
monoclonal antibodies, such as bevacizumab, may help the body's immune system attack the
cancer, and may interfere with the ability of tumor cells to grow and spread. It is not yet
known whether combination chemotherapy is more effective when given with or without
bevacizumab after surgery in treating patients with ovarian, epithelial, primary peritoneal,
or fallopian tube cancer.
Stanford is currently not accepting patients for this trial.
For more information, please contact Sharanya Ramasubramanian, 650-723-0622.
Stanford Investigators
View full details
-
Efficacy Multicentre Trial of ImmunoTherapy Vaccination With Abagovomab to Treat Ovarian Cancer Patients
Not Recruiting
More
The purpose of this study is to evaluate the benefit of vaccination with Abagovomab, an
experimental immunotherapy in ovarian cancer patients. The benefit will be evaluated in terms
of time the remission status is kept as well as prolongation of life expectancy.
Stanford is currently not accepting patients for this trial.
For more information, please contact Fitzsimmons Colleen, 6507243155.
Stanford Investigators
View full details
-
Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer
Not Recruiting
More
This randomized phase III trial studies pelvic radiation therapy to see how well it works
compared with vaginal implant radiation therapy, paclitaxel, and carboplatin in treating
patients with high-risk stage I or stage II endometrial cancer. Radiation therapy uses
high-energy x-rays to kill tumor cells. Implant radiation therapy uses radioactive material
placed directly into or near a tumor to kill tumor cells. Drugs used in chemotherapy, such as
paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either
by killing the cells, by stopping them from dividing, or by stopping them from spreading. It
is not yet known whether pelvic radiation therapy alone is more effective than vaginal
implant radiation therapy, paclitaxel, and carboplatin in treating patients with endometrial
cancer.
Stanford is currently not accepting patients for this trial.
For more information, please contact Maureen Sutton, 6507259167.
Stanford Investigators
View full details
-
Second Curettage in Treating Patients With Persistent Non-metastatic Gestational Trophoblastic Tumors
Not Recruiting
More
This phase II trial studies how well a second curettage (removal of the abnormal cancer cells
in the uterus using a method of surgically removing the lining of the uterus) works in
treating patients with gestational trophoblastic tumors that did not go away after a first
curettage (persistent) and has not yet spread to other places in the body (non-metastatic). A
second curettage may be effective in treating persistent gestational trophoblastic tumors and
may decrease the likelihood that patients will need chemotherapy in the near future.
Stanford is currently not accepting patients for this trial.
For more information, please contact Maureen Sutton, 6507259167.
Stanford Investigators
View full details
-
Trabectedin in Treating Patients With Advanced, Persistent, or Recurrent Leiomyosarcoma of the Uterus
Not Recruiting
More
RATIONALE: Drugs used in chemotherapy, such as trabectedin, work in different ways to stop
the growth of tumor cells, either by killing the cells or by stopping them from dividing.
PURPOSE: This phase II trial is studying how well trabectedin works in treating patients with
advanced, persistent, or recurrent leiomyosarcoma of the uterus.
Stanford is currently not accepting patients for this trial.
For more information, please contact Maureen Sutton, 6507259167.
Stanford Investigators
View full details
-
Combination Study Of SB-485232 (Interleukin 18) And Doxil For Advanced Stage Epithelial Ovarian Cancer
Not Recruiting
More
The purpose of this study is to identify a dose of SB-485232 which is safe, tolerable and
biologically active when used in combination with pegylated liposomal doxorubicin (Doxil) in
patients with epithelial ovarian cancer. This study will use a standard treatment regimen of
pegylated liposomal doxorubicin (Doxil) in combination with rising doses of SB-485232. The
dose selected from this study will be used in a future studies to evaluate the efficacy of
this combination.
Stanford is currently not accepting patients for this trial.
For more information, please contact Anthea Buchin, 6507243155.
Stanford Investigators
View full details
-
Efficacy of Panobinostat in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma
Not Recruiting
More
This study is designed to assess the effectiveness of the combination of Panobinostat plus
Bortezomib and Dexamethasone in patients with relapsed and bortezomib refractory Multiple
Myeloma.
Stanford is currently not accepting patients for this trial.
For more information, please contact Maureen Sutton, 6507259167.
Stanford Investigators
View full details
